Art. -Nr.: HY-B0594

Iohexol

5 Cited Publications

Kundenbewertung

Based on 5 publication(s) in Google Scholar

Iohexol is a non-ionic, water-soluble contrast agent used as a reference marker for the determination of glomerular filtration rate (GFR) at the level of renal function. Iohexol can be used for contrast in myelography, computerized tomography (cisternography, ventriculography) and MicroCT imaging.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.54%
CAS. Nr.: 66108-95-0
Formel: C₁₉H₂₆I₃N₃O₉
Molecular Weight:821.14

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Iohexol Chemical Structure

CAS. Nr.: 66108-95-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (5)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

Iohexol (150 mg I/mL, 0-24 h) inhibits the cell viability of NRK 52-E^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:

NRK 52-E
Concentration:

150 mg I/mL
Incubation Time:

0-24 h
Result:

Reduced the MTT conversion at 12 and 24 h.
Inhibited mitochondrial dehydrogenase activity at 12 and 24 h.

In Vivo

Iohexol (0.25-4 mL/kg, p.o., weekly) promotes the differentiation of dogs intestinal segments after application of 0.5-2.0 mL/kg^[4].
Iohexol (64.7 mg/kg, i.v.) can be used to evaluate glomerular filtration rate (GFR) in healthy or dogs with presenting chronic kidney disease (CKD)^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Healthy dogs ^[4]
Dosage:

0.25-4 mL/kg
Administration:

Oral gavage (p.o.), weekly
Result:

Peaked the iohexol serum concentrations between 2 and 4 hours.
Reduced radiolucency after application of 0.25 mL/kg and 4 mL/kg.
Included watery diarrhea after ingestion of 4 mL/kg.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 66108-95-0
Appearance Solid
Molecular Weight 821.14
Formel C₁₉H₂₆I₃N₃O₉
Color White to off-white
SMILES

O=C(C1=C(I)C(N(C(C)=O)CC(O)CO)=C(I)C(C(NCC(O)CO)=O)=C1I)NCC(O)CO
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (5)

All Histological Imaging/StainingFlow CytometryCell Migration/Invasion AssayCell Imaging/Staining

Sort by:

Journal Impact Factor

Sci Rep

Iodine nanoparticles enhance radiotherapy of intracerebral human glioma in mice and increase efficacy of chemotherapy. [Abstract]

2019 Mar 14;9(1):4505. PMID: 30872755
Sci Rep

Small, Long Blood Half-Life Iodine Nanoparticle for Vascular and Tumor Imaging. [Abstract]

2018 Sep 14;8(1):13803. PMID: 30218059

Iohexol purchased from MedChemExpress. Usage Cited in: Sci Rep. 2018 Sep 14;8(1):13803. [Abstract]

At 2 minutes post-injection, the widely used iodine contrast agent iohexol had accumulated in the kidneys while INPs continued to opacify renal vasculature.

Iohexol purchased from MedChemExpress. Usage Cited in: Sci Rep. 2018 Sep 14;8(1):13803. [Abstract]

MicroCT coronal views of mouse 30 min after IV injection of INP or Iohexol (Both with 1.75 g I/kg IV injection). Vascularization is clearly seen at this time with the INPs.
IUBMB Life

Contrast-Induced Acute Kidney Injury is Modulated by Circadian CLOCK/NRF2 Pathway. [Abstract]

2025 May;77(5):e70022. PMID: 40391788
BMC Nephrol

Sodium selenite attenuates inflammatory response and oxidative stress injury by regulating the Nrf2/ARE pathway in contrast-induced acute kidney injury in rats. [Abstract]

2024 Jul 15;25(1):226. PMID: 39009991
Physiol Res

The Role of Mdivi-1 in Reducing Mitochondrial Fission via the NF-kappaB/JNK/SIRT3 Signaling Pathway in Acute Kidney Injury. [Abstract]

2025 Mar 24;74(1):79-92. PMID: 40126145

Iohexol purchased from MedChemExpress. Usage Cited in: Physiol Res. 2025 Mar 24;74(1):79-92. [Abstract]

Flow cytometry results in control, Iohexol (100 mgI/mL), Genta, or Cisplatin group.

Iohexol purchased from MedChemExpress. Usage Cited in: Physiol Res. 2025 Mar 24;74(1):79-92. [Abstract]

Migration ability of HK-2 cells in each group. Cell growth photographed under a microscope after culture for 24 h and 48 h in control, Iohexol, Genta, or Cisplatin group; value of migration rate.

Iohexol purchased from MedChemExpress. Usage Cited in: Physiol Res. 2025 Mar 24;74(1):79-92. [Abstract]

Expression of ROS in HK-2 cells in each group. Laser confocal microscopy photograph in control, Iohexol-3 (administered 3 μM of Mdivi-1), Iohexol, Genta-1 (treated with 1 μM of Mdivi-1), Genta, Cisplatin-5 (treated with 5 μM of Mdivi-1), or Cisplatin group; ROS level in each group.

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : ≥ 50 mg/mL (60.89 mM)

DMSO : 50 mg/mL (60.89 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2178 mL

6.0891 mL

12.1782 mL

5 mM

0.2436 mL

1.2178 mL

2.4356 mL

10 mM

0.1218 mL

0.6089 mL

1.2178 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 120 mg/mL (146.14 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Soman RS, et al. Development and validation of an HPLC-UV method for determination of iohexol in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 25;816(1-2):339-43. [Content Brief]

[2]. Hainfeld JF, Ridwan SM, Stanishevskiy Y, Smilowitz NR, Davis J, Smilowitz HM. Small, Long Blood Half-Life Iodine Nanoparticle for Vascular and Tumor Imaging. Sci Rep. 2018 Sep 14;8(1):13803. [Content Brief]

[3]. Jensen H, et al. The effects of the iodinated X-ray contrast media iodixanol, iohexol, iopromide, and ioversol on the rat kidney epithelial cell line NRK 52-E. Ren Fail. 2011;33(4):426-33. [Content Brief]

[4]. Klenner S, et al. Estimation of intestinal permeability in healthy dogs using the contrast medium iohexol. Vet Clin Pathol. 2009 Sep;38(3):353-60. [Content Brief]

[5]. Baklouti S, et al. Population Pharmacokinetic Model of Iohexol in Dogs to Estimate Glomerular Filtration Rate and Optimize Sampling Time. Front Pharmacol. 2021 Apr 29;12:634404. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	1.2178 mL	6.0891 mL	12.1782 mL	30.4455 mL
	5 mM	0.2436 mL	1.2178 mL	2.4356 mL	6.0891 mL
	10 mM	0.1218 mL	0.6089 mL	1.2178 mL	3.0445 mL
	15 mM	0.0812 mL	0.4059 mL	0.8119 mL	2.0297 mL
	20 mM	0.0609 mL	0.3045 mL	0.6089 mL	1.5223 mL
	25 mM	0.0487 mL	0.2436 mL	0.4871 mL	1.2178 mL
	30 mM	0.0406 mL	0.2030 mL	0.4059 mL	1.0148 mL
	40 mM	0.0304 mL	0.1522 mL	0.3045 mL	0.7611 mL
	50 mM	0.0244 mL	0.1218 mL	0.2436 mL	0.6089 mL
	60 mM	0.0203 mL	0.1015 mL	0.2030 mL	0.5074 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Iohexol

5 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Iohexol

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Pancreatic Cancer Compound Library

Mitochondria-Targeted Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Cell Death Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Publications Citing Use of MedChemExpress (MCE) Iohexol

Biologische Aktivität

Chemical Information

Publications (5)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Iohexol

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Pancreatic Cancer Compound Library

Mitochondria-Targeted Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Cell Death Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Publications Citing Use of MedChemExpress (MCE) Iohexol

Biologische Aktivität

Chemical Information

Publications (5)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Iohexol Related Classifications

HY-B0594 Related Classifications